Aducanumab: Set for FDA Advisory Committee Review
June 7, 2021 update: In a long-awaited decision, the Food and Drug Administration on Monday, June 7, approved Aducanumab as the first new medication for Alzheimer’s disease in nearly two decades and the first to treat the underlying pathology of [View More]